Company Directory / Medical Device

NovoCure logo

Public · NASDAQ:NVCRFor profitMedical DeviceZug, Switzerland, Switzerland

NovoCure

An Oncology Company Pioneering a Novel Therapy for Solid Tumors

Founded
2000
26 years ago
Staff
1001-5000
1,425 on LinkedIn
Followers
60k
on LinkedIn
Funding
$1.0B
as listed, USD

We are a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields. Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. We have ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small… Read all

We are a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields. Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. We have ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. Headquartered in Switzerland, Novocure has U.S. operations in Portsmouth, New Hampshire and Chesterbrook, Pennsylvania. Additionally, Novocure has offices in Canada, Germany, Japan, Poland and Israel.

Set against six million companies

Size

1-1011-5051-100101-250251-500501-10001k-5k5k-10k10k+

1001-5000 people: larger than 97% of companies with a size listed. 1,425 people list it on LinkedIn.

Age

200019002026

26 years old.

Reach

Website ranked #1,346,489 in the world for traffic, about 19k visits a month. 60,456 followers on LinkedIn.

What it does

BiotechnologyHealth CareMedical DeviceOncologyMedical DeviceOncologyCancerGlioblastomaNeuro-Oncology

Funding, as listed

$1.0B raised in total

  • Rounds7
  • LatestPost ipo debt, May 2024
  • Latest amountUSD 100,000,000
  • Investors8, 3 leading

What the source datasets report. We have not watched these rounds ourselves, and do not hold this company in the startups database.

FoundersWilliam F. Doyle, Yoram Palti
Apps1

Every detail we hold

Everything the source datasets list about NovoCure, field by field. Contact details are held but never shown.

The company

Name
NovoCure
Type
For profit
Status
Public · NASDAQ:NVCR
Founded
2000
Founders
William F. Doyle, Yoram Palti
Industry
Medical Device
Categories
Biotechnology, Health Care, Medical Device, Oncology
Specialities
Medical Device, Oncology, Cancer, Glioblastoma, Neuro-Oncology

Where

City
Zug
Region
Switzerland
Country
Switzerland
Markets
Southern US

Size and reach

Staff band
1001-5000
People on LinkedIn
1,425
LinkedIn followers
60,456
Web traffic rank
#1,346,489
Monthly web visits
19,445
Apps
1

Funding, as listed

Total
$1,003,542,095 USD
Rounds
7
Latest round
Post ipo debt
Latest round date
May 2024
Latest amount
100,000,000 USD
Investors
8
Lead investors
3
Stock listing
NASDAQ:NVCR
Listing status
public

About this record

Sources
Crunchbase, LinkedIn
Last imported
Sept 2026

Growth, as the source summarises it

NovoCure reported mixed financial results for Q4 and the full year 2023. The company also reported its first quarter 2024 financial results. Additionally, NovoCure secured a new $400 million multi-tranche non-dilutive debt financing from Pharmakon.

Summaries written by the source dataset, not by us, and not checked.

Companies like it

Medical Device in Switzerland.

See all in the directory →

From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 36,795 companies in Switzerland and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.